MedImmune LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00263783
- Locations
- ๐ซ๐ท
Institut Gustave Roussy, Villejuf, France
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: MEDI 517Other: Aluminum hydroxide
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00263744
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
Phase 2
Completed
- Conditions
- -Unhealthy Children With a History of Prematurity
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00240929
- Locations
- ๐บ๐ธ
Packard Children's Hospital at Stanford, Palo Alto, California, United States
Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: AV024Other: Placebo
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2008-11-20
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 330
- Registration Number
- NCT00240877
- Locations
- ๐บ๐ธ
SFBC International Inc, Miami, Florida, United States
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
Phase 4
Completed
- Conditions
- Chronic Lung Disease
- Interventions
- Biological: Lyophilized PalivizumabBiological: Liquid Palivizumab
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 417
- Registration Number
- NCT00233064
- Locations
- ๐บ๐ธ
Boston University Medical Center, Boston, Massachusetts, United States
๐บ๐ธAll for Kids Pediatric Clinic, Little Rock, Arkansas, United States
๐บ๐ธPediatric Association of Fall River, Fall River, Massachusetts, United States
Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults
Phase 1
Completed
- Conditions
- Healthy Japanese Male Adults
- Interventions
- Biological: CAIV-TBiological: Placebo
- First Posted Date
- 2005-09-23
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00224783
Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 3000
- Registration Number
- NCT00217230
- Locations
- ๐ฟ๐ฆ
Department of Family & Primary Care, Faculty of Medicine, University of Stellenbosch, Tygerberg, South Africa
Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children
Phase 3
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1920
- Registration Number
- NCT00192374
- Locations
- ๐ต๐ญ
Department of Microbiology, Research Institute for Tropical Medicine, Muntinlupa City, Philippines
๐น๐ญQueen Sirikit National Institute of Child Health (Children's Hospital), Bangkok, Thailand
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Cold-adapted influenza vaccine trivalent (CAIV-T)Biological: Trivalent Inactivated Vaccine (TIV)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-03-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 3009
- Registration Number
- NCT00192413
- Locations
- ๐ฟ๐ฆ
Jansen van Rensburg, Amanzimtoti, South Africa
๐ฟ๐ฆDocnor House, Durban North, Dwazulu Natal, South Africa
๐ฟ๐ฆHazelmed Family Practice, Hazelwood, Pretoria, South Africa
Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Biological: CAIV-T
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 498
- Registration Number
- NCT00192270
- Locations
- ๐ง๐ช
University of Antwerp, Antwerp, Belgium
๐ง๐ชDienst Jeugdgezondheidszorg, Leuven, Belgium
๐ซ๐ฎOulu University Hospital, Oulu, Finland
ยฉ Copyright 2025. All Rights Reserved by MedPath